FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W165724281> ?p ?o ?g. }

• W165724281 endingPage "654" @default.
• W165724281 startingPage "654" @default.
• W165724281 abstract "Abstract Background In the Stop imatinib study (STIM)1, we previously demonstrated that Imatinib could be safely discontinued in patients with a sustained deep molecular response (DMR) (undetectable BCR-ABLtranscripts (UMRD) for at least 2 years) (Lancet oncology, 2010;11: 1029-1035). Recently, these results were confirmed by the Australasian TWISTER study using criteria of imatinib cessation very similar to those used in the STIM1 study (Blood, 2013; 122:515-22). However in the both studies, half of the patients were previously treated with IFN leading to a non-homogenous cohort of patients. So we conducted prospectively a second trial (STIM2) where cessation of imatinib treatment was proposed for patients in sustained DMR who were treated only with imatinib. Methods In this new multicenter, non-randomized STIM2 study (ClinicalTrials.gov, NCT01343173), imatinib was discontinued in CML pts with the same criteria as those we reported previously for the STIM1 i.e. sustained DMR defined as remission lasting more than 2 consecutive years and confirmed on five datapoints of BCR–ABL analyses by quantitative RT-PCR during these 2 years. The UMRD was defined with a sensitivity> to 4.5 log with ≥ 50.000 ABL transcripts amplified as internal control. The molecular relapse was defined as positivity of BCR–ABL transcript in Quantitative RT-PCR confirmed by a second analysis point indicating the increase of one log in relation to the first analysis point, on two successive assessments, or loss of MMR at one point. Quantitative RT-PCR for BCR–ABL transcripts from peripheral blood was performed every month during the first year and every 2 months thereafter. Beyond 2 years, molecular biology FU was performed every 3 months. Results From April 2011 to June 2013, 124 CML pts were included (62 men,62 women) with a median age of 61 years recruited in the 23 French centers. At the last update, the median follow up of the first 124 pts enrolled is 12 months (range 1-25). After discontinuation of imatinib, a molecular relapse occurred in 48 pts (45 relapses during the first 6 months and 3 relapses between 6 and 12 month), and 76 patients were still free of treatment at the last update with DMR. However 41 experienced a BCR-ABL RQ-PCR fluctuation without clear molecular relapse. In this so-called-fluctuation group of patients, 7 were found positive once, 6 twice, 12 patients between 3 and 5 times, 10 patients between 6 and 10 times and 6 patients more than 10 times confirming that BCR-ABL reappearance does not mean automatically clinical relapse. We confirmed also that all patients were sensitive to a TKI re-challenge. Actually, 33 patients were retreated with imatinib 5 with nilotinib and 3 with dasatinib. The median time to achieve again a CMR from the molecular relapse was 7 months (range 4-16 months) and from re-initiation of TKI was 4 months (range 2-14). Taking into account the cost of imatinib and the number of months without treatment in the total study population at last analysis, the savings within the STIM2 trial were estimated at 2.8 millions Euros. Conclusion We confirm that Imatinib can be safely and prospectively discontinued in pts with DMR of at least 2 years duration in patients only treated with imatinib. To stop treatment it may not require the complete eradication of residual leukemic stem cells since positive fluctuation PCR results do not lead to CML relapse or progression. These intriguing results, even for imatinib treated patients since disease onset (already observed after IFN therapy), are comparable to those reported with the more sensitive PCR on DNA in the TWISTER study and are under investigations in our laboratory. Disclosures: Mahon: Novartis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Brisol Myers Squibb: Consultancy, Honoraria; Ariad: Honoraria; Pfizer: Honoraria. Nicolini:Novartis, Ariad, Teva, BMS and Pfizer: Honoraria from Novartis, Ariad, Teva, BMS and Pfizer. Grants from Novartis. Other. Rea:Novartis: Honoraria; Bristol Myers Squibb: Honoraria; Pfizer: Honoraria; Ariad: Honoraria. Etienne:novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Membership on an entity’s Board of Directors or advisory committees; Ariad: Membership on an entity’s Board of Directors or advisory committees." @default.
• W165724281 created "2016-06-24" @default.
• W165724281 creator A5000074573 @default.
• W165724281 creator A5007750346 @default.
• W165724281 creator A5016240673 @default.
• W165724281 creator A5029315909 @default.
• W165724281 creator A5041434329 @default.
• W165724281 creator A5043794507 @default.
• W165724281 creator A5046360304 @default.
• W165724281 creator A5052564121 @default.
• W165724281 creator A5055797334 @default.
• W165724281 creator A5068342352 @default.
• W165724281 creator A5070207000 @default.
• W165724281 creator A5075844368 @default.
• W165724281 creator A5078121817 @default.
• W165724281 creator A5079181777 @default.
• W165724281 creator A5082189560 @default.
• W165724281 date "2013-11-15" @default.
• W165724281 modified "2023-09-30" @default.
• W165724281 title "Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib" @default.
• W165724281 doi "https://doi.org/10.1182/blood.v122.21.654.654" @default.
• W165724281 hasPublicationYear "2013" @default.
• W165724281 type Work @default.
• W165724281 sameAs 165724281 @default.
• W165724281 citedByCount "36" @default.
• W165724281 countsByYear W1657242812013 @default.
• W165724281 countsByYear W1657242812015 @default.
• W165724281 countsByYear W1657242812016 @default.
• W165724281 countsByYear W1657242812017 @default.
• W165724281 countsByYear W1657242812018 @default.
• W165724281 countsByYear W1657242812019 @default.
• W165724281 countsByYear W1657242812020 @default.
• W165724281 countsByYear W1657242812021 @default.
• W165724281 countsByYear W1657242812022 @default.
• W165724281 countsByYear W1657242812023 @default.
• W165724281 crossrefType "journal-article" @default.
• W165724281 hasAuthorship W165724281A5000074573 @default.
• W165724281 hasAuthorship W165724281A5007750346 @default.
• W165724281 hasAuthorship W165724281A5016240673 @default.
• W165724281 hasAuthorship W165724281A5029315909 @default.
• W165724281 hasAuthorship W165724281A5041434329 @default.
• W165724281 hasAuthorship W165724281A5043794507 @default.
• W165724281 hasAuthorship W165724281A5046360304 @default.
• W165724281 hasAuthorship W165724281A5052564121 @default.
• W165724281 hasAuthorship W165724281A5055797334 @default.
• W165724281 hasAuthorship W165724281A5068342352 @default.
• W165724281 hasAuthorship W165724281A5070207000 @default.
• W165724281 hasAuthorship W165724281A5075844368 @default.
• W165724281 hasAuthorship W165724281A5078121817 @default.
• W165724281 hasAuthorship W165724281A5079181777 @default.
• W165724281 hasAuthorship W165724281A5082189560 @default.
• W165724281 hasConcept C126322002 @default.
• W165724281 hasConcept C143998085 @default.
• W165724281 hasConcept C203092338 @default.
• W165724281 hasConcept C2777583451 @default.
• W165724281 hasConcept C2778729363 @default.
• W165724281 hasConcept C3019892230 @default.
• W165724281 hasConcept C535046627 @default.
• W165724281 hasConcept C71924100 @default.
• W165724281 hasConcept C72563966 @default.
• W165724281 hasConcept C90924648 @default.
• W165724281 hasConceptScore W165724281C126322002 @default.
• W165724281 hasConceptScore W165724281C143998085 @default.
• W165724281 hasConceptScore W165724281C203092338 @default.
• W165724281 hasConceptScore W165724281C2777583451 @default.
• W165724281 hasConceptScore W165724281C2778729363 @default.
• W165724281 hasConceptScore W165724281C3019892230 @default.
• W165724281 hasConceptScore W165724281C535046627 @default.
• W165724281 hasConceptScore W165724281C71924100 @default.
• W165724281 hasConceptScore W165724281C72563966 @default.
• W165724281 hasConceptScore W165724281C90924648 @default.
• W165724281 hasIssue "21" @default.
• W165724281 hasLocation W1657242811 @default.
• W165724281 hasOpenAccess W165724281 @default.
• W165724281 hasPrimaryLocation W1657242811 @default.
• W165724281 hasRelatedWork W1921369781 @default.
• W165724281 hasRelatedWork W1991789019 @default.
• W165724281 hasRelatedWork W2071522917 @default.
• W165724281 hasRelatedWork W2120077570 @default.
• W165724281 hasRelatedWork W2123135404 @default.
• W165724281 hasRelatedWork W2150181285 @default.
• W165724281 hasRelatedWork W2153928148 @default.
• W165724281 hasRelatedWork W2165746197 @default.
• W165724281 hasRelatedWork W3080142768 @default.
• W165724281 hasRelatedWork W2028346583 @default.
• W165724281 hasVolume "122" @default.
• W165724281 isParatext "false" @default.
• W165724281 isRetracted "false" @default.
• W165724281 magId "165724281" @default.
• W165724281 workType "article" @default.